Boston Scientific closes $435M acquisition of Symetis

Boston Scientific Corporation announced the close of its acquisition of Symetis SA, a Swiss structural heart company, for $435 million in cash. The deal was originally announced on March 30, 2017.

“Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices.”news.bostonscientific.com

• 2 sources
• news.bostonscientific.comBoston Scientific Closes Symetis AcquisitionMay 16, 2017
• truffle.comTruffle Capital announces the close of Symetis acquisition for $435 million by Boston Scientific – Truffle CapitalMay 17, 2017

Summarized from public sources; check the original articles before acting on it.